Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene.
Demma MJ, Mapelli C, Sun A, Bodea S, Ruprecht B, Javaid S, Wiswell D, Muise E, Chen S, Zelina J, Orvieto F, Santoprete A, Altezza S, Tucci F, Escandon E, Hall B, Ray K, Walji A, O'Neil J. Demma MJ, et al. Among authors: muise e. Mol Cell Biol. 2019 Oct 28;39(22):e00248-19. doi: 10.1128/MCB.00248-19. Print 2019 Nov 15. Mol Cell Biol. 2019. PMID: 31501275 Free PMC article.
ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells.
Singh L, Muise ES, Bhattacharya A, Grein J, Javaid S, Stivers P, Zhang J, Qu Y, Joyce-Shaikh B, Loboda A, Zhang C, Meehl M, Chiang DY, Ranganath SH, Rosenzweig M, Brandish PE. Singh L, et al. Among authors: muise es. Mol Cancer Res. 2021 Apr;19(4):702-716. doi: 10.1158/1541-7786.MCR-20-0622. Epub 2020 Dec 28. Mol Cancer Res. 2021. PMID: 33372059
STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors.
Perera SA, Kopinja JE, Ma Y, Muise ES, Laskey J, Chakravarthy K, Chen Y, Cui L, Presland J, Sathe M, Javaid S, Minnihan EC, Ferguson HM, Piesvaux J, Pan BS, Zhao S, Sharma SK, Woo HC, Pucci V, Knemeyer I, Cemerski S, Cumming J, Trotter BW, Tse A, Khilnani A, Ranganath S, Long BJ, Bennett DJ, Addona GH. Perera SA, et al. Among authors: muise es. Mol Cancer Ther. 2022 Feb;21(2):282-293. doi: 10.1158/1535-7163.MCT-21-0136. Epub 2021 Nov 23. Mol Cancer Ther. 2022. PMID: 34815361
Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models.
Georgiev P, Muise ES, Linn DE, Hinton MC, Wang Y, Cai M, Cadzow L, Wilson DC, Sukumar S, Caniga M, Chen L, Xiao H, Yearley JH, Sriram V, Nebozhyn M, Sathe M, Blumenschein WM, Kerr KS, Hirsch HA, Javaid S, Olow AK, Moy LY, Chiang DY, Loboda A, Cristescu R, Sadekova S, Long BJ, McClanahan TK, Pinheiro EM. Georgiev P, et al. Among authors: muise es. Mol Cancer Ther. 2022 Mar 1;21(3):427-439. doi: 10.1158/1535-7163.MCT-21-0561. Mol Cancer Ther. 2022. PMID: 34965960 Free PMC article.
Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI.
Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, Zhang BB, Bonaldo P, Chua S, Scherer PE. Khan T, et al. Among authors: muise es. Mol Cell Biol. 2009 Mar;29(6):1575-91. doi: 10.1128/MCB.01300-08. Epub 2008 Dec 29. Mol Cell Biol. 2009. PMID: 19114551 Free PMC article.
Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
Tan Y, Muise ES, Dai H, Raubertas R, Wong KK, Thompson GM, Wood HB, Meinke PT, Lum PY, Thompson JR, Berger JP. Tan Y, et al. Mol Pharmacol. 2012 Jul;82(1):68-79. doi: 10.1124/mol.111.076679. Epub 2012 Apr 10. Mol Pharmacol. 2012. PMID: 22496518
BET Bromodomain Inhibition Suppresses Human T Cell Function.
Georgiev P, Wang Y, Muise ES, Bandi ML, Blumenschein W, Sathe M, Pinheiro EM, Shumway SD. Georgiev P, et al. Immunohorizons. 2019 Jul 11;3(7):294-305. doi: 10.4049/immunohorizons.1900037. Immunohorizons. 2019. PMID: 31356159 Free article.
Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells.
Wang Y, Cui L, Georgiev P, Singh L, Zheng Y, Yu Y, Grein J, Zhang C, Muise ES, Sloman DL, Ferguson H, Yu H, Pierre CS, Dakle PJ, Pucci V, Baker J, Loboda A, Linn D, Brynczka C, Wilson D, Haines BB, Long B, Wnek R, Sadekova S, Rosenzweig M, Haidle A, Han Y, Ranganath SH. Wang Y, et al. Oncoimmunology. 2021 Mar 18;10(1):1896643. doi: 10.1080/2162402X.2021.1896643. Oncoimmunology. 2021. PMID: 33796403 Free PMC article.
61 results